Open an account

Nevro LLC

NVRO · NYSE

Price unavailable right now.

No price history for this range.

About NVRO

Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,099 full-time employees. The firm is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its product portfolio includes both spinal cord stimulation (SCS) treatment therapy for certain forms of neuropathic pain and minimally invasive treatment options for patients suffering from chronic sacroiliac (SI) joint pain. The firm has developed and commercialized its HFX SCS platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform being its latest addition to the Senza family of products. Its HFX Therapy and 10 kHz Therapy are designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, PDN Indication Approval, NSBP Approval, Senza HFX iQ System, and others.

Employees
1,099
Headquarters
Redwood City, California
Listed
Nov 6, 2014
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
nevro.com

NVRO key statistics

This section is temporarily unavailable. Refresh to try again.

NVRO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 30.8% on average.

  1. Q1 FY23: reported -$0.98 per share against an estimate of -$1.06
  2. Q2 FY23: reported -$0.69 per share against an estimate of -$0.7045
  3. Q3 FY23: reported -$0.65 per share against an estimate of -$0.784
  4. Q4 FY23: reported -$0.25 per share against an estimate of -$0.499
  5. Q1 FY24: reported -$0.58 per share against an estimate of -$1.07
  6. Q2 FY24: reported -$0.53 per share against an estimate of -$0.6984
  7. Q3 FY24: reported -$0.41 per share against an estimate of -$0.8276
  8. Q4 FY24: reported -$0.40 per share against an estimate of -$0.7895

NVRO news

  • Press releaseBusiness Wire

    NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO

  • Press releasePRNewswire

    Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, PLYA, NVRO on Behalf of Shareholders

  • Press releasePRNewswire

    Shareholder Alert: The Ademi Firm investigates whether Nevro Corp. is obtaining a Fair Price for its Public Shareholders

  • Press releasePRNewswire

    Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm

  • Press releaseBusiness Wire

    NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, PLYA on Behalf of Shareholders

  • Press releasePRNewswire

    Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm

Similar companies

Companies in the same industry as Nevro LLC

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.